Bets on October rate-cut overblown as Fed a ’reluctant dove,’ Macquarie warns
Shelly Pinto, the Senior Vice President of Finance and Chief Accounting Officer at ALX Oncology Holdings Inc. (NASDAQ:ALXO), recently sold 550 shares of the company’s common stock. The transaction, which took place on February 19, 2025, was executed at a weighted average price of $1.1502 per share, resulting in a total sale value of approximately $632.
The sale was conducted to satisfy tax obligations associated with the vesting of restricted stock units, as noted in the filing. Following this transaction, Pinto holds 87,352 shares of ALX Oncology. The shares were sold in multiple transactions at prices ranging from $1.15 to $1.16. Despite recent market challenges, InvestingPro data shows the company maintains strong liquidity with a current ratio of 4.82 and holds more cash than debt on its balance sheet. Track insider transactions and access 10+ additional ProTips with an InvestingPro subscription.
In other recent news, ALX Oncology presented positive outcomes from its ASPEN-06 Phase 2 clinical trial, demonstrating a significant tumor response in HER2-positive advanced gastric cancer patients treated with evorpacept in combination with other therapies. The trial reported an overall response rate (ORR) of 41.3% in the intent-to-treat population, surpassing historical control groups. Particularly, patients with confirmed HER2-positive cancer showed an ORR of 48.9% and a median duration of response (mDOR) of 15.7 months. Following these results, the U.S. Food and Drug Administration granted Fast Track designation for evorpacept for second-line treatment of HER2-positive gastric cancer.
Analyst firms have responded to these developments with mixed adjustments. UBS cut its price target for ALX Oncology to $2.20 from $4.00 but maintained a Buy rating, citing the need for further investigation into evorpacept’s efficacy. Stifel maintained a Hold rating with a $3.00 target, noting the potential benefits of evorpacept in combination treatments. Cantor Fitzgerald reaffirmed its Overweight rating, emphasizing the promising results for confirmed HER2+ patients. Meanwhile, H.C. Wainwright lowered its price target to $5 from $25 but kept a Buy rating, reflecting changes in market expectations and competitive dynamics. These recent developments underscore ALX Oncology’s ongoing efforts in advancing cancer treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.